This syndrome was initially recognized in the setting of organ transplantation 1 and then also reported in patients following hematopoietic SCT (HSCT). [2] [3] [4] [5] However, the clinical aspects of CIPS in HSCT remain unclear. Thus, records of patients who developed CIPS after HSCT in our hospital were retrospectively reviewed.
Between September 2003 and December 2010, 560 patients underwent allogeneic HSCT in our hospital. Of these, 10 (1.8%; 5 males, 5 females) developed CIPS. Patient characteristics are summarized in Table 1 . Median age was 32 years (range, 18-59 years). Two patients developed CIPS after their second transplantation (case 1, 7). The CI was administered from day À1, initially as a continuous infusion, at doses of 3 mg/kg per day for CsA and 0.02-0.03 mg/kg per day for FK, and the doses of CIs were adjusted to maintain levels at 200-300 ng/mL for CsA and 10-15 ng/mL for FK, respectively. CIPS was mainly diagnosed by one or both of severe, disabling pain bilaterally in the lower extremities or intolerable, antihistamine-resistant dermal pruritus without a skin rash. Bone scintigraphy was performed for a definitive diagnosis in some patients.
For GVHD prophylaxis, four patients received CsA, and five received FK. One patient (case 5) received CsA initially but was switched to FK because of intestinal acute GVHD on day 17 after HSCT. The median onset of CIPS from starting CIs was 17 days (range, 3-889 days). Eight patients developed CIPS within 30 days after CI administration, whereas two developed CIPS after more than 300 days. With respect to trough levels of CIs, two patients were below, three were within and four were above the target range. Acute GVHD was observed in five patients, but only two received systemic steroid therapy. Bone scintigraphy was carried out in four patients, all of whom suffered from leg pain, and three patients (75%) showed increased bone uptake. Of note, increased bone uptake was also seen in areas that were not painful in two patients (cases 3 and 5; Figure 1 ).
With respect to the treatment and outcome of CIPS, CI was discontinued in three patients, another CI was substituted in four and the CI dose was reduced in one. Symptoms in all of these patients improved and analgesics could be terminated in six of seven patients. Of interest, Previously reported cases.
Letter to the Editor trough CI levels were sufficiently maintained for the prophylaxis of GVHD in three patients after switching CIs, and none of them developed CIPS again. In patients who had discontinued CIs, one (case 2) experienced an exacerbation of acute GVHD. Two others who had discontinued CIs were late-onset cases and showed no obvious signs of GVHD. Exacerbation of GVHD was also seen in case 10. However, her CI trough level was lower than that of the other patients (cases 7 and 8).
These results show that CIPS in HSCT occurs mainly at an early stage of administration of CIs, and it can develop irrespective of the trough levels and the type of CI. In contrast, CIPS often occurs at a late stage (X6 weeks) in solid organ transplantation. 1 The reason for this discrepancy is unclear. Patients with hematological diseases have received many neurotoxic drugs, such as chemotherapeutic agents, before HSCT and they also receive many drugs during their HSCT, which may either contribute to or predispose the patients to this complication including the timing of onset. Bone scintigraphy seems to be a useful tool for making the diagnosis of CIPS, especially for patients with leg pain. The adjustment of CIs is essential for the treatment of CIPS; the present results suggest that switching CIs is the best method, and CI concentration can be safely and adequately maintained for the prophylaxis of GVHD. Although only one patient received diltiazem in our small cohort (Table 1) , calcium channel blockers have been reported to be effective for CIPS. 6 Thus, these drugs should be considered when initial treatment is less effective. The pathogenesis of CIPS remains unclear, but vascular disturbance of bone perfusion and permeability or facilitation of pronociceptive processes by interrupting glial function and by inhibition of nuclear factor-activated T-cells has been postulated. 1, 7 A recent report also showed that some patients with human herpes virus 6 (HHV-6) reactivation manifested CIPS-like symptoms. 8 As HHV-6 was measured in only one patient (case 5) and was negative, the association between CIPS and HHV-6 reactivation is unclear. Thus, further investigation will be necessary to clarify the etiology of CIPS, including a potential association with viral infection.
